Equities
TechnologySoftware & Computer Services
  • Price (USD)142.68
  • Today's Change-2.31 / -1.59%
  • Shares traded761.87k
  • 1 Year change-10.46%
  • Beta1.3075
Data delayed at least 15 minutes, as of Jul 11 2020 00:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.

  • Revenue in USD (TTM)11.16bn
  • Net income in USD215.00m
  • Incorporated2016
  • Employees67.00k
  • Location
    IQVIA Holdings Inc4820 Emperor BlvdDURHAM 27703-8426United StatesUSA
  • Phone+1 (919) 998-2000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.iqvia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
EXACT Sciences Corporation1.06bn-106.63m13.80bn4.11k--5.42--13.00-0.7663-0.76637.7716.980.34094.4910.83258,411.40-3.42-14.64-3.66-15.9375.9872.26-10.04-40.255.81-5.540.3775--92.82244.8052.04--70.67--
Cardinal Health Inc153.59bn-4.16bn14.41bn49.50k--11.98--0.0938-14.04-14.04519.754.123.7511.5318.183,102,748.00-10.142.60-24.916.024.535.16-2.710.72680.52867.550.857659.416.389.83300.443.225.679.50
Alnylam Pharmaceuticals, Inc.285.93m-886.42m18.63bn1.32k--13.60--65.15-8.03-8.032.5911.930.13320.69825.23216,124.00-41.29-35.69-46.58-39.3687.75---310.01-600.534.48--0.00--193.3634.16-16.24--32.78--
AmerisourceBergen Corp.186.16bn1.58bn19.74bn22.00k12.785.509.760.1067.597.59886.8517.664.6016.1112.978,461,793.003.942.1116.508.732.782.780.85520.44350.625315.640.52843.626.948.48-21.7523.773.2411.22
Incyte Corporation2.23bn-376.05m22.77bn1.46k--11.73--10.21-1.74-1.7410.248.930.80979.247.491,531,188.00-13.663.65-16.214.3795.6396.02-16.874.763.38--0.02580.0014.7133.37308.16--22.87--
BioMarin Pharmaceutical Inc.1.81bn114.01m22.80bn3.00k206.517.03101.4512.630.61040.61049.8717.920.39430.61544.57601,590.102.49-4.792.91-5.5678.8680.386.31-15.011.72-2.090.2101--14.2717.8669.11--6.90--
McKesson Corporation231.05bn906.00m23.19bn80.00k28.504.5511.320.10045.024.991,264.3031.433.8213.1012.102,888,138.001.862.836.018.005.205.530.48730.79930.5981.670.52418.067.815.231,809.43-12.59-1.4710.76
Moderna Inc52.57m-505.59m24.27bn830.00--14.12--461.72-1.50-1.500.15614.430.0271--7.5663,340.96-26.10---28.25-------961.70------0.0232---55.42---27.91------
Iqvia Holdings Inc11.16bn215.00m27.25bn67.00k131.424.9218.462.441.091.0956.3329.020.4832--4.38166,537.301.101.501.321.8333.8933.192.272.88--1.930.67570.006.4915.22-14.73-11.7347.75--
Seattle Genetics, Inc.956.03m-313.72m30.18bn1.61k--17.05--31.57-1.86-1.865.6810.230.5190.835.01595,656.10-17.03-14.09-19.49-16.7693.4090.52-32.82-27.334.18-8.100.00--40.0226.1728.76--32.73--
Data as of Jul 11 2020. Currency figures normalised to IQVIA Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

34.54%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202018.88m9.89%
BlackRock Fund Advisorsas of 31 Mar 20208.77m4.60%
SSgA Funds Management, Inc.as of 31 Mar 20207.94m4.16%
Longview Partners LLPas of 31 Mar 20206.88m3.61%
Jackson Square Partners LLCas of 31 Mar 20205.10m2.67%
AllianceBernstein LPas of 31 Mar 20204.90m2.57%
Janus Capital Management LLCas of 31 Mar 20204.03m2.11%
Farallon Capital Management LLCas of 31 Mar 20203.74m1.96%
Steadfast Capital Management LPas of 31 Mar 20202.85m1.49%
Lazard Asset Management LLCas of 31 Mar 20202.85m1.49%
More ▼
Data from 31 Mar 2020 - 31 Mar 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.